Bob van Oosten

As a clinical neurologist and researcher I have been active in the field of multiple sclerosis (MS) since 1993. My main focus has been on the efficacy and mode of action of anti T-cell, anti-TNF therapies and cytokine-based therapies and their side effects in MS. With the arrival of anti-B-cell therapies in clinical practice early 2018, clinical researchers will have the opportunity to study several aspects of anti B-cell therapy in much more detail, mainly in MS, but also in less prevalent related diseases such as neuromyelitis spectrum disorder (NMO-SD).


VU University Medical Center, Department of Neurology, Amsterdam, The Netherlands
VU University Medical Center, MS Center, Amsterdam, The Netherlands